Circulating microRNAs miR-331 and miR-195 differentiate local luminal a from metastatic breast cancer by McAnena, Peter et al.
University of Massachusetts Medical School 
eScholarship@UMMS 
Open Access Articles Open Access Publications by UMMS Authors 
2019-05-10 
Circulating microRNAs miR-331 and miR-195 differentiate local 
luminal a from metastatic breast cancer 
Peter McAnena 
National University of Ireland, Galway 
Et al. 
Let us know how access to this document benefits you. 
Follow this and additional works at: https://escholarship.umassmed.edu/oapubs 
 Part of the Biological Factors Commons, Cancer Biology Commons, Computational Biology 
Commons, Diagnosis Commons, Neoplasms Commons, and the Nucleic Acids, Nucleotides, and 
Nucleosides Commons 
Repository Citation 
McAnena P, Tanriverdi K, Curran C, Gilligan K, Freedman JE, Brown JA, Kerin MJ. (2019). Circulating 
microRNAs miR-331 and miR-195 differentiate local luminal a from metastatic breast cancer. Open 
Access Articles. https://doi.org/10.1186/s12885-019-5636-y. Retrieved from 
https://escholarship.umassmed.edu/oapubs/3840 
Creative Commons License 
This work is licensed under a Creative Commons Attribution 4.0 License. 
This material is brought to you by eScholarship@UMMS. It has been accepted for inclusion in Open Access Articles 
by an authorized administrator of eScholarship@UMMS. For more information, please contact 
Lisa.Palmer@umassmed.edu. 
RESEARCH ARTICLE Open Access
Circulating microRNAs miR-331 and miR-
195 differentiate local luminal a from
metastatic breast cancer
Peter McAnena1 , Kahraman Tanriverdi2, Catherine Curran1, K. Gilligan1, Jane E. Freedman2,
James A. L. Brown1* and Michael J. Kerin1*
Abstract
Background: Breast cancer is the leading cause of cancer related death in women, with metastasis the principle
cause of mortality. New non-invasive prognostic markers are needed for the early detection of metastasis,
facilitating treatment decision optimisation. MicroRNA (miRNA) are small, non-coding RNAs regulating gene
expression and involved in many cellular processes, including metastasis. As biomarkers, circulating miRNAs
(in blood) hold great promise for informing diagnosis or monitoring treatment responses.
Methods: Plasma extracted RNA from age matched local Luminal A (n = 4) or metastatic disease (n = 4) were
profiled using Next Generation Sequencing. Selected differentially expressed miRNA were validated on a whole
blood extracted miRNA cohort [distant metastatic disease (n = 22), local disease (n = 31), healthy controls (n = 21)].
Area Under the Curve (AUC) in Receiver Operating Characteristic (ROC) analyses was performed.
Results: Of 4 miRNA targets tested (miR-181a, miR-329, miR-331, miR-195), mir-331 was significantly over-expressed
in patients with metastatic disease, compared to patients with local disease (p < 0.001) or healthy controls
(p < 0.001). miR-195 was significantly under-expressed in patients with metastatic disease, compared to patients
with local disease (p < 0.001) or healthy controls (p = 0.043). In combination, miR-331 and miR-195 produced an
AUC of 0.902, distinguishing metastatic from local breast cancer.
Conclusions: We identified and validated two circulating miRNAs differentiating local Luminal A breast cancers
from metastatic breast cancers. Further investigation will reveal the molecular role of these miRNAs in metastasis,
and determine if they are subtype specific. This work demonstrates the ability of circulating miRNA to identify
metastatic disease, and potentially inform diagnosis or treatment effectiveness.
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Background
Breast cancer is the most common cancer among women
and the fifth leading cause of cancer death, with metastasis
the principle cause of mortality [1]. Despite considerable re-
cent advances in both diagnosis and treatment 20–30% of
breast cancer patients will present with, or develop, distant
metastatic disease [2]. The risk of developing metastatic
disease is determined by the initial stage at detection, as
well as tumour subtype and access to appropriate therapy.
Breast cancer consists of at least four clinically relevant mo-
lecular subtypes: Luminal A, Luminal B, HER2-enriched
and triple-negative [3]. Luminal A is the most common
subtype, comprising up to 60% of all breast cancers [4, 5].
Bone is the most frequent site of metastasis among all sub-
types, with a recent study (in > 240,000 cases) showing that
58.52% of metastasis in Luminal A was to the bone, with
an incidence of 3.1% [6]. Luminal A patients remain at con-
siderable risk of metastasis after 5 years in contrast to
triple-negative patients, who tend to develop metastases in
the first 3 years following diagnosis [7]. New, non-invasive,
biomarkers capable of augmenting conventional diagnostic
and prognostic modalities in metastatic breast cancer are
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the key to facilitating truly individualised treatment (and
disease monitoring) regimens.
MicroRNAs (miRNA) are small, non-coding RNAs that
regulate gene expression by targeting messenger RNA,
resulting in either translational repression or RNA degrad-
ation [8]. Over 4000 miRNAs have been described, and it
is estimated that they regulate up to 30% of all human
genes [9]. MiRNAs can operate as tumour-suppressors or
tumour-promoters and their dysregulation is intricately
linked to cellular processes involved in the metastatic cas-
cade, such as sustained proliferation, angiogenesis and
epithelial-mesenchymal transition (EMT) [10, 11]. Circu-
lating miRNAs show great promise in contributing to the
diagnosis, prognosis, evaluation of response to therapy
and treatment of breast cancer [12–15]. MiRNAs are
stable in circulation and can be quantified relatively simply
and inexpensively (using real-time quantitative reverse
transcriptase PCR; RT-qPCR) [16–18].
The aim of our study was to identify and validate cir-
culating miRNAs capable of distinguishing metastatic
breast cancer from locally confined breast cancer in Lu-
minal A patients. We utilised Next Generation Sequen-
cing (NGS) to profile circulating miRNAs, with selected
differentially expressed miRNAs validated in an inde-
pendent cohort (including healthy controls). Building on
our previous work which identified mir-195 as a circu-
lating biomarker in breast cancer [16], we further inves-
tigated if miR-195 was a biomarker for Luminal A or
metastasis. Additionally, the selected target miRNA were
combined and tested as part of a miRNA signature, for
an improved ability to identify metastatic disease.
Methods
Patient selection
Samples were selected from a prospectively maintained
Biobank (2008–2015) collected from breast cancer pa-
tients (primarily from the west coast of Ireland) treated at
a tertiary referral unit (Galway University Hospital, Gal-
way Ireland). The discovery cohort was composed of
plasma samples from patients with Luminal A disease me-
tastasized to the bone, and patients with locally confined
Luminal A breast cancer (n = 4) (Table 1). The validation
cohort (n = 74) was comprised of whole blood samples
from 22 patients with distant metastasized Luminal A dis-
ease (17 to bone), patients with locally confined Luminal
A breast cancer (n = 31) and healthy age matched controls
(n = 21) (Table 2). All breast cancer patients in the study
had histologically confirmed Luminal A breast cancer;
hormone receptor positive and HER2/neu negative. Re-
ceptor status was taken from routine clinical evaluation
records [ER/PR status determined using immunohisto-
chemistry as per ASCO guidelines, ALLRED score ≥ 3 (1–
10% weakly positive cells). HER2 receptor status was iden-
tified by Herceptest, with a score of 3+ considered posi-
tive. Any + 2 inconclusive results were confirmed using
FISH testing as per ASCO guidelines, with a HER2/
CEP17 ratio greater than two considered amplified]. Meta-
static patients had confirmed distant metastatic disease by
biopsy/imaging or both, at the time samples were col-
lected. Blood was obtained from the locally confined
breast cancer patients pre-operatively and these patients
had no evidence of subsequent recurrence or metastasis
(mean follow up of 7.2 years). No patients received
neo-adjuvant chemotherapy. Age-matched healthy control
blood samples were collected from women residing in the
same catchment area as the cancer cases. Women provid-
ing control samples were interviewed by a clinician in ad-
vance of sample collection, confirming there was no
Table 1 Discovery cohort clinicopathological details
Clinicopathological details Metastatic (n = 4) Local (n = 4)
Age - mean years 61 65
Histological Subtype Ductal (n = 4) Ductal (n = 4)
Molecular Subtype Luminal A (n = 4) Luminal A (n = 4)
Stage IV (n = 4) II (n = 2)
III (n = 2)
Metastasis location Bone (n = 4) –
Time Sample Taken M1 at presentation (n = 1)
Metastatic at follow
up (n = 3)
Pre-operatively
(n = 4)
Table 2 Validation cohort clinicopathological details
Clinicopathological
details
Metastatic
(n = 22)
Local (n = 31) Healthy
Controls
(n = 21)
Age - mean years (SD) 60 (±15 years) 54 (±12 years) 52
(±12 years)
Histological
Subtype
Ductal (n = 17)
Lobular (n = 5)
Ductal
(n = 31)
–
Molecular Subtype Luminal A
(n = 22)
Luminal A
(n = 31)
–
Stage IV (n = 22) I (n = 10)
II (n = 17)
III (n = 4)
–
Tumour Grade 1 (n = 6)
2 (n = 17)
3 (n = 8)
–
Nodal Status N positive
(n = 11)
N negative
(n = 20)
–
Metastasis
location
Bone (n = 17)
Lung (n = 3)
Liver (n = 2)
– –
Time Sample
Taken
M1 at presentation
(n = 14)
Metastatic at
follow up (n = 8)
Pre-operatively
(n = 31)
–
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personal history of malignancy, or current inflammatory
or infectious conditions.
RNA extraction
RNA was isolated from plasma samples (500 μl) using a
miRNeasy Serum/Plasma Kit (Qiagen) and a
semi-automated QIAcube platform (Qiagen), both as per
the manufactures instructions. Whole blood RNA was
extracted from venous non-fasting whole blood samples
collected in BD vacutainers® containing 18 mg dipotas-
sium EDTA anticoagulant (BD-Plymouth, PL6 7BP, UK).
Total RNA was extracted from whole blood (1 ml) using
TRI Reagent BD (Molecular Research Centre, Inc) as
previously described [19]. RNA concentration was deter-
mined by NanoDrop spectrophotometry (NanoDrop
ND-1000 Technologies Inc., DE, USA).
Library preparation for RNA sequencing
Small-RNA libraries were constructed using NEXTflex
Small RNA Sequencing Kit (Ion PGM & Ion Proton
Compatible, Bioscientific) as per the manufactures
instructions.
Next generation sequencing
Next Generation Sequencing (maximum 200 nucleotide
read) performed using the Ion PI Sequencing 200 Kit v2
(Life Technologies, USA) and Ion PI Chip Kit v2 BC as
per the manufactures instructions, on the Ion Proton
System (Life Technologies, USA).
Next generation sequencing data analysis
Analysis was performed as previously described using the
exceRpt pipeline [15]. Briefly, the ExceRpt pipeline [15]
utilizes assesses microRNAs (miRNAs) using a series of
read-alignment processes calculated to eliminate potential
contaminants. Key steps include: .3′ adapter clipping
(adapter removal accomplished using the fastx v.0.0.13
clipper tool; http://hannonlab.cshl.edu/fastx_toolkit/);
Quality control and [removal of probable contaminant se-
quences using Bowtie2 and UniVec (NCBI common con-
taminant sequences library) and human ribosomal RNA
(rRNA) precursor sequences (45S, 5S and mitochondrial
rRNA sequences)]; sRNAbench software tool analysis [15]
[for each sample, identical clipped-read sequences are
counted and collapsed to a single entry, reads containing
N’s are removed, and using Bowtie1 mapped (to the hu-
man genome and pre-miRNA sequences from miRBase
v21, allowing a single mismatched base in each align-
ment). The alignment outcomes (pre-miRNA and
mature-miRNA IDs) are parsed and used in conjunction
with Vienna software]; Reads not previously aligned are
mapped against small-RNA libraries (including tRNAs
from gtRNAd, piRNAs from RNAdb, snoRNAs from
snoRNA-LBME-db snRNAs, other RNA sequences from
RFam); Finally, any outstanding unmapped reads are
aligned (using sRNAbench), to the annotated plant and
virus pre-miRNA sequences in miRBase (complete set).
Validation by RT-qPCR
RT-qPCR of target miRNA was performed using TaqMan
miRNA assays (Applied Biosystems). Following RNA iso-
lation, 100 ng of total RNA was reverse transcribed using
stem-loop primers and MultiScribe reverse transcriptase.
PCR reactions were performed in triplicate with inter
assay control (IAC) used. RQ-PCR performed using stand-
ard thermal-cycling conditions (7900HT Fast Real-Time
PCR System, Applied Biosystems). Raw fluorescence
(cycle threshold, CT) data were subsequently calculated.
High Cq values indicated low miRNA expression. The
threshold standard deviation for intra- and inter-assay
replicates was 0.3. PCR amplification efficiencies (E) were
calculated for each miRNA and Taqman miRNA assay
using the formula E = (10–1/slope− 1) × 100, using the
slope of the semi-log regression plot of Cq versus log
input of cDNA (10-fold dilution series of five points).
A threshold of 10% above or below 100% was adopted.
Cq values were scaled to highest expressing sample
and normalized to previously validated miRNA con-
trols (miR-16 and miR-425) [20]. MiRNA expression
was calculated by the comparative cycle threshold
(ΔCq) method, using qbasePLUS software (Biogazelle,
NV, Belgium). Persistent Cq value > 35 considered out-
side viable detection thresholds.
Statistical analysis
Statistical analysis was performed using SPSS (IBM SPSS
Statistics for Macintosh, v23.0., IBM). The
Kolmogorov-Smirnov test for normality was conducted.
Data were log transformed (log10) for analysis when
non-normal distribution was identified. Significance and
associations of circulating miRNA levels were determined
using the Mann-Whitney U test, t-test, ANOVA, Spear-
man’s Rho or Pearson correlation, as appropriate. Results
with p-value < 0.05 were deemed to be significant. Binary
logistic regression analysis was used and receiver operating
characteristic (ROC) curves generated to evaluate the
ability of chosen miRNAs to distinguish between metastatic
and local breast cancer patients. This was performed both
individually and for combinations of miRNAs.
Ethics, consent and permissions
This study was conducted in accordance with the
granted National University of Ireland Galway and Uni-
versity College Hospital Galway ethical approval. All pa-
tients clinic-pathological and demographic data were
obtained from a prospectively maintained database.
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Results
Circulating miRNA profiling of luminal a breast cancers
and target selection
The discovery cohort identified 712 miRNAs (miR), of
which 16 miRNAs were found to be significantly (p < 0.005)
differentially expressed, between the metastatic and locally
confined Luminal A breast cancer groups (Table 3). Three
of these miRNAs were chosen for further validation
(miR-181a, miR-329 and miR-331), selected based on evi-
dence in the literature of their involvement in metastatic
processes (Table 4). A fourth miRNA (miR-195) was chosen
for investigation, based on a minimum 1.5 fold change in
expression in the discovery cohort, and our previous work
demonstrating miR-195 as a circulating biomarker in breast
cancer [16].
Target miRNA as metastatic or local breast cancer
biomarkers
The selected targets were validated on RNA extracted
from the whole blood from 3 cohorts of patients, locally
confined Luminal A breast cancer (n = 31), metastatic
breast cancer (n = 22) and healthy controls (n = 21).
Expression of miR-331 was significantly higher in the meta-
static group compared to both the locally confined breast
cancer group (p < 0.001) and the healthy control group (p <
0.001), corresponding to an average fold-change of 2.58 and
2.94 respectively. There was no significant difference in
miR-331 expression between the locally confined breast can-
cer group and the control group (p= 0.825) (Fig. 1a).
Investigating miR-181a, its expression was significantly
higher in the healthy control group in comparison to the
metastatic group (p = 0.001), or the locally confined
breast cancer group (p = 0.02), with an average
fold-change of 1.4 and 1.19 respectively (Fig. 1b). Ex-
pression of miR-181a was lower in the metastatic group,
compared to the local group (p = 0.059).
Examining expression of miR-195, it was significantly
lower in the metastatic group compared to both locally
confined breast cancer (p < 0.001) and healthy control
groups (p = 0.043), with average fold-changes of 0.6 and
0.73 respectively (Fig. 1c). Interestingly, there was no sig-
nificant difference in miR-195 expression between the
locally confined breast cancer and the healthy control
group (p = 0.087).
mir-329 was detectable in only 2 of the metastatic co-
hort (n = 13; with a mean Cq of 34.95) and detectable in
11 of the local cohort (n = 17; mean Cq 35.9) (data not
shown). Due to the variability of this expression/detec-
tion further analysis of miR-329 was not performed.
Target miRNA as breast cancer biomarkers
Pooling metastatic and local cancer groups together (n =
53) there was a significantly higher expression of miR-331
(p < 0.001) in cancer samples, compared to healthy con-
trols (Fig. 2 a). The cancer group had a significantly lower
expression of miR-181a (p < 0.001) (Fig. 2b). There was no
significant difference for miR-195 (0 = 0.806) (Fig. 2c).
Correlating target miRNA with clinicopathological
features
The association of the target miRNA expression with key
clinically relevant clinicopathological features was exam-
ined. Investigating expression in locally confined breast
cancer group (n = 31) comparing lymph node positive dis-
ease (n = 11) to lymph node negative disease (n = 20) there
was no significant difference for miR-331 (p = 0.099),
miR-181a (p = 0.7) or miR-195 (p = 0.674) (Fig. 3a-c).
There was no significant difference found between tumour
grades (I-III) for miR-331 (p = 0.274), miR-181a (p = 0.6)
or miR-195 (p = 0.37) (Fig. 4a-c). However, previous work
demonstrated that changes in miR-195 expression corre-
lated with disease stage (1–4) [16].
No significant difference between lymphovascular in-
vasion (LV invasion) status (positive/negative) was ob-
served for miR-331 (p = 0.31), miR-181a (p = 0.3) or
Table 3 Top 10 differentially expressed miRNA, between local and metastatic breast cancers, in discovery cohort
Rank miRNA baseMean log2FoldChange lfcSE stat P value
1 hsa-miR-487a-5p 10.204322 −6.5949809 2.08622397 −3.1612046 0.00157118
2 hsa-miR-376c-3p 9.66930256 −6.2249402 2.16041009 −2.8813697 0.00395951
3 hsa-miR-181a-2-3p* 10.0812243 6.10481296 2.17498667 2.80682775 0.0050032
4 hsa-miR-6721-5p 11.0766671 −5.5985336 2.00252808 −2.7957329 0.00517822
5 hsa-miR-329-3p* 40.6587497 −4.2606132 1.5758723 −2.7036539 0.00685817
6 hsa-miR-665 4.33646293 −5.5104353 2.17214494 −2.5368635 0.01118505
7 hsa-miR-331-3p* 9.380562 −4.2942354 1.79092278 −2.3977781 0.01649485
8 hsa-miR-4433a-5p 15.8475709 3.90544954 1.65092455 2.36561359 0.01800022
9 hsa-miR-2277-3p 3.59270664 −4.7490645 2.08789239 −2.2745734 0.02293153
10 hsa-miR-6734-5p 25.3078788 3.92134038 1.73154349 2.26465024 0.02353415
*Selected miRNAs in bold
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miR-195 (p = 0.79) (Additional file 1: Figure S1A-C). Ex-
ploring any correlation between the target miRNA ex-
pression and tumour size, no significant correlation was
found for miR-331 (p = 0.233), miR-181a (p = 0.942) or
miR-195 (p = 0.175) (Additional file 1: Figure S2A-C).
miRNA signature as a biomarker of metastatic luminal a
breast cancers
A logistic regression was performed to ascertain the com-
bined ability of the target circulating miRNAs miR-195,
miR-181a and miR-331 to distinguishing metastatic from
local disease. Analysing each individual miRNA, and the
combination of miRNAs, the area under the curve (AUC)
produced from receiver operator characteristic (ROC)
curve generation using binary logistic regression was com-
pared. The highest AUC of 0.902 was achieved combining
miR-331 and miR-195, providing a sensitivity of 95% and
a specificity of 76% (Fig. 5). The logistic regression model
was significant [x2 (4)=28.98, p < 0.001]. Combining
miR-181a with miR-195 [AUC of 0.86 (p = 0.35)] or
miR-331 [AUC of 0.88 (p = 0.174)] did not contribute
significantly to any biomarker signature (ROC Curves:
Additional file 1: Figure S3A-B).
Discussion
Despite considerable investment into the development of
biomarkers and advances in our understanding of the
underlying molecular landscape of breast cancer, only
three established biomarkers (ER, PR, HER2) are manda-
torily screened for in all newly diagnosed breast cancer pa-
tients. While these markers categorise breast cancer (into
standardised, clinically relevant subtypes) and predict re-
sponse to treatment, there remains a need for further bio-
markers to better stratify high-risk patients and to
monitor for the development of metastasis in real time.
A variety of clinical multigene/multiprotein tests capable
of evaluating prognosis independent of traditional prog-
nostic factors (such as grade and size) and are commer-
cially available. Oncotype DX [21, 22], Mammaprint [23]
and urokinase plasminogen activator (uPA)/PAI-1 [24, 25]
have been evaluated in terms of their clinical utility in ran-
domised prospective trials. These multi-analyte tests re-
quire invasive collection of tumour tissue, and their use is
Table 4 Candidate miRNAs implicated in the metastatic cascade
miRNA Metastatic
process
Expression
Pattern
Cancer
Mir-181a EMT
Migration and
Invasion
↑
↑
Breast [48]
Colorectal [44]
Breast [49]
Mir-329 Proliferation and
migration
Apoptosis
↓
↓
↓
Neuroblastoma [50]
Gastric [51]
Lung [52]
Mir-331 Proliferation and
EMT
↑ Liver [37]
Fig. 1 Target miRNA expression in Luminal A breast cancer groups
and controls. RT-qPCR of target miRNA in indicated groups; locally
confined Luminal A breast cancer (Local) (n = 31); metastatic breast
cancer (Metastatic) (n = 22) and healthy controls (Control) (n = 21).
a miR-331 expression. b miR-181a expression. c miR-195 expression.
p < 0.05 considered significant. p values indicated on figure
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Fig. 2 Target miRNA expression in breast cancer. RT-qPCR of
indicated target miRNA in indicated groups. Breast Cancers (Cancer)
(n = 53), Controls (n = 21). a miR-331. b miR-181a. c miR-195. p < 0.05
considered significant. p values indicated on figure
Fig. 3 Target miRNA expression in breast cancers, by node status.
RT-qPCR of indicated target miRNA in cancers, by nodal status
(positive or negative). a miR-331. b miR-181a. c miR-195. p < 0.05
considered significant. p values indicated on figure
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limited to informing treatment decisions for early stage
breast cancers.
Non-invasive biomarker testing which can identify dis-
ease progression is of greater clinical value through easy,
rapid access to samples, which can allow improved mon-
itoring and the early identification of metastatic breast
cancer. Traditional circulating markers include CA 15–
3, CA 125 and CEA. While these have not been recom-
mended for serial measurement by ASCO or ESMO [26,
27], increasing levels of these markers in breast cancer
patients have been shown to precede the development of
metastases, and in conjunction with prompt appropriate
imaging can lead to improved therapeutic interventions,
and patient outcomes [28, 29].
A number of new circulating biomarkers of metastatic
disease have been investigated in recent years. Circulating
tumour cells (CTCs) are quantifiable in blood and detec-
tion of > 5 (per 7.5 ml of whole blood) is associated with
increased baseline levels of metastatic niches, and is an in-
dependent prognostic factor of relapse [30]. Cell free cir-
culating tumour DNA (ctDNA) contains cancer specific
somatic mutations and can be detected using qRT-PCR
[31]. Detection of ctDNA in plasma following curative
treatment can precede the clinical diagnosis of breast can-
cer metastasis with high accuracy [32, 33]. However, both
of these require relatively large sample volumes to accur-
ately detect tumour cells/DNA into the blood and they
are not suitable for monitoring treatment response (com-
pared to disease occurrence/presence). Additionally,
CTC’s detection requires expression of known and some-
times variable markers (with high quality antibodies
needed for the profiling). CTC or ctDNA genomic profil-
ing needs known genomic changes and the support of
Fig. 4 Target miRNA expression, by breast cancer grade. RT-qPCR of
indicated target miRNA in cancers, by breast cancer grade: I (n = 10),
II (n = 17), III (n = 4). a miR-331. b miR-181a. c miR-195. p < 0.05
considered significant. p values indicated on figure
Fig. 5 miRNA signature significantly distinguishes local from
metastatic Luminal A breast cancer. a The signature of miR-331 and
miR-195 distinguish metastatic from local breast
cancer (AUC = 0.902)
McAnena et al. BMC Cancer          (2019) 19:436 Page 7 of 10
high quality interpretation and analysis services to make
sense of the data [34]. In contrast, miRNA can be detected
in small volumes of blood, analysis is simple, and import-
antly they and can be used to directly monitor tumour re-
sponses to treatments.
As we enter the era of tailored breast cancer manage-
ment clinicians require multiple tests, allowing disease
detection/screening, aiding in treatment choice, and to
monitor disease response, ultimately to achieve the opti-
mal outcome for patients. Circulating miRNAs are an
appealing adjunct to conventional diagnostic and prog-
nostic modalities, as they are stable in circulation, easily
quantifiable and can reveal further information of the
underlying biology of the tumour. The potential of miR-
NAs to contribute to a “liquid biopsy” has been the
focus of much research in recent years [35]. In this study
2 novel miRNA (mir-331 and miR-191a) and (expanding
on our previous work [16]) mir-195 were validated as
markers of distant metastatic Luminal A breast cancer,
compared to patients with locally confined Luminal A
breast cancer or age-matched healthy controls.
Investigating the molecular role of each of these vali-
dated miRNA, we find that confirmed targets of Mir-331
include HER2, HOTAIR, E2F1 and DOHH, with estab-
lished links to metastatic processes such as cell prolifera-
tion, evasion of apoptosis, angiogenesis and EMT [36]. A
recent study investigating mir-331 in hepatocellular car-
cinoma demonstrated that high expression of mir-331 as-
sociated with poor clinicopathological details and worse
survival [37]. mir-331 was shown to target PHLPP (PH
domain and leucine-rich repeat protein phosphatase)
resulting in stimulation of protein kinase B (AKT) pro-
moting EMT, proliferation and metastasis. Inhibition of
mir-331 in vivo (in a xenograft mouse model using an
anti-mir-331 vector) resulted in a marked inhibition of
proliferation and metastasis, further supporting the desig-
nation of mir-331 as a tumour-promoting miRNA.
Mir-195 has previously been implicated as a diagnostic
biomarker of breast cancer [16, 38], and has more recently
been investigated as a tumour suppressor. Mir-195 has
been shown to target Bcl-2, inducing apoptosis, and target
FASN, HMGCR, ACACA and CYP27B1 in
hormone-receptor positive breast cancer cell lines, sup-
pressing tumour growth, EMT, invasion and metastasis [39,
40]. Other studies have shown that mir-195 regulates bio-
logical processes such as cell proliferation and cell cycle by
targeting CDK4, CDK6, cyclin D1 and others [41–43].
miR-181a functions as a tumour suppressor, with
re-expression of miR-181a inhibiting proliferation, mi-
gration, and invasion and promoting apoptosis (though
regulation of Bcl-2) in cancer cells [44, 45]. Changes in
miR-181a expression in AML tumours correlated with
increased survival and improved treatments responses in
a sub-cohort of patients [46]. Together these results
point to a role for miR-181 in regulating tumour growth
and metastasis in multiple cancers. While there are re-
ports of divergent miRNA profiles between plasma and
whole blood, our results support previous work confirm-
ing miR-195 expression in both [47]. It is likely that dif-
ferences in miRNA expression seen are (at least
partially) due to different collection methods and equip-
ment, and the relative quantifiable expression levels
retained after processing and RNA extraction.
Our results are encouraging and further advance the po-
tential of circulating miRNAs as biomarkers that can con-
tribute to breast cancer management. Further work is
needed, using a larger, blinded multi-centre prospective
study to fully validate our chosen miRNA as biomarkers
of metastatic breast cancer. Our study was limited to ER
positive, Luminal A breast cancer patients, and it is un-
clear if the dyseregulated miRNAs are subtype specific or
if the same pattern of expression exists in all breast cancer
subtypes. In the metastatic cohort our samples were taken
at the time the patient had confirmed distant metastatic
disease, and while our results suggest these miRNAs re-
flect the presence of metastasis, prospective collection of
blood samples from patients with locally confined disease
need to be conducted to confirm if the dysregulated
miRNA expression preceded the development of meta-
static disease. It is worth noting that the patient cohort in-
vestigated in this study were recruited almost entirely
from the West of Ireland, potentially limiting the wide-
spread applicability of these results. Additional studies are
needed to investigate the potential clinical validity of these
findings in other patient cohorts (multiple, independent
and varied geographic and ethnic populations).
Conclusion
Our study identified and validated two circulating miR-
NAs with differential expression able to separate meta-
static from locally confined Luminal A breast cancer. Our
results demonstrate that patients with metastatic disease
have a higher expression of mir-331 and a lower expres-
sion of mir-195 in their circulation. In combination, these
markers form a signature able to distinguish metastatic
from local breast cancer with a high sensitivity and specifi-
city. While miR-195 has previously been investigated as a
suppressor of metastatic disease in breast cancer [40], to
our knowledge this is the first study to identify mir-331 as
a potential promoter of breast cancer metastasis. Further
research is required to elucidate the molecular mecha-
nisms/activity of miR-331 and to establish if miR-331 dys-
regulation contributes to the development of metastatic
disease, of if it is a consequence of the metastatic changes.
Our work contributes to the evolving understating of the
molecular dysregulation in breast cancer and provides bio-
markers that may contribute to the optimization of breast
cancer management.
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Additional file
Additional file 1: Figure S1. Target miRNA expression in breast cancer,
by lymphovascular invasion (LV invasion) status. A. miR-181 expression. B.
miR-331 expression. C. miR-195 expression. Note: expression of miR-329
was below/outside detection threshold, with persistent Cq value > 35 in
over 50% of samples. Figure S2. miRNA expression in breast cancer does
not correlate with tumour size. A. miR-181 expression. B. miR-331
expression. C. miR-195 expression. Figure S3. miRNA signature
combinations that did not significantly distinguish local from metastatic
Luminal A breast cancer. ROC curves: A. miR-181 and miR-195. B.
miR-331 and miR-181. (PDF 611 kb)
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